Roig García J J, Jiménez Murillo L M, Clemente Millán M J, González Barranco J M, Segura Saint-Gerons J, Montero Pérez F J
Unidad Funcional de Urgencias, Hospital Universitario Reina Sofía, Córdoba.
Rev Clin Esp. 1994 Aug;194(8):594-8.
We studied 89 patients diagnosed in our emergency department of paroxysmal supraventricular tachycardia, to describe the efficacy and safety of intravenous adenosine triphosphate (ATP) in their treatment. All received a first bolus of 10 mg of ATP and if no electrical response was observed, a second dose of 20 mg. This treatment was successful in 91% of the patients, lasting of 26.9 seconds to resolve the episode, and in the 53% of the patients with the first dose. In 9% of the patients ATP did not resolve the episode but allowed to diagnose it, which in five patients was atrial flutter, in 2 Wolff-Parkinson-White syndrome and in one atrial fibrillation. Adverse effects appeared in 25.6% of the cases, being in all transitory and banal. ATP is a very effective and safe drug for the treatment of patients with PSVT.
我们对在我院急诊科诊断为阵发性室上性心动过速的89例患者进行了研究，以描述静脉注射三磷酸腺苷（ATP）治疗该病的有效性和安全性。所有患者均首先静脉推注10mg ATP，若未观察到电反应，则给予第二剂20mg。该治疗在91%的患者中取得成功，发作缓解持续时间为26.9秒，53%的患者使用第一剂即成功。9%的患者使用ATP后发作未缓解，但有助于明确诊断，其中5例为心房扑动，2例为预激综合征，1例为心房颤动。25.6%的病例出现不良反应，均为短暂且轻微的。ATP是治疗阵发性室上性心动过速患者的一种非常有效且安全的药物。
